ClinicalTrials.gg
Not yet recruitingNCT06165822Updated Dec 12, 2023

A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets

A Phase 1 interventional study of TQB3909 tablets and Itraconazole capsule in Advanced Malignant Neoplasm, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-12.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of Itraconazole Capsules/Rifampicin Capsules on pharmacokinetics of TQB3909 tablets in vivo, and the safety of TQB3909 tablets and combined with Itraconazole Capsules/Rifampicin Capsules after single oral dose.

02

Conditions studied

  • Advanced Malignant Neoplasm

Keywords

  • Drug drug interaction
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At the time of signing the , males or females of between 18 and 45 years of age;
  • Female weight ≥45 kg, male weight ≥50 kg, with a (BMI) between 19 and 26 kg/m2.
  • Subjects in good health, as determined by a medical history, vital signs, physical examination, 12-lead (ECG) and clinical laboratory evaluations;
  • Subjects can comply with the study procedures, voluntarily participate in the study, and sign the informed consent in person.

Exclusion criteria

Exclusion Criteria:

  • Subjects: pre-existing or existing circulatory system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematology, immunology, psychiatry and metabolic disorders mental diseases or abnormalities, or related chronic or acute diseases, which were not appropriate to participate in the trial as assessed by the investigators ;
  • Subjects with systemic/local acute infection presented before study drug administration;
  • Subjects who have a history of specific allergies, or allergies;
  • Subjects who have difficulty in swallowing or have any gastrointestinal disorder that affects drug absorption at the time of screening;
  • Subjects who cannot receive venous indwelling needle for blood sample collection;
  • Subjects who cannot tolerate venous puncture or have a history of needle or blood sickness;
  • Subjects who drank regularly within the 6 months prior to the first dosing, such as those who drank more than 14 units of alcohol per week or who had a positive alcohol breath test at the time of screening;
  • Subjects who had a history of major surgery, had taken the study drug, or had participated in other drug clinical trials within 3 months prior to the first dosing;
  • Subjects who donated blood or lost significant amounts of blood within 3 months prior to the first dosing;
  • Subjects who had used drugs within 3 months prior to the first dosing, or tested positive for drugs, or had a history of drug abuse within 5 years prior to screening;
  • Subjects who smoked more than 5 cigarettes per day within the 3 months prior to the first dosing or who could not stop using any tobacco products during the trial;
  • Subjects who consumed excessive amounts of tea, coffee, and/or caffeinated beverages daily within the 30 days prior to the first dosing;
  • Subjects who have used any drug that inhibits or induces liver metabolism of the drug within the 30 days prior to the first dosing;
  • Subjects who have taken any prescription, over-the-counter, herbal, or health product within the 14 days prior to the first dosing;
  • Subjects who have taken a special diet or other factors affecting drug absorption, distribution, metabolism, or excretion within 7 days prior to the first dosing;
  • Subjects who ingested chocolate, any caffeinated, or xanthine-rich food or drink within 48 hours before the first dosing;
  • Subjects who have special dietary requirements and cannot follow a uniform diet;
  • Female subjects of ;
  • Subjects judged by the investigators to be unsuitable to participate.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Itraconazole drug-durg interaction (DDI)

    Itraconazole capsules, 0.2g once daily from Day 3 to Day 10 TQB3909 tablets, single oral dose on Day 1 and Day 8.

    Drug: TQB3909 tablets · Drug: Itraconazole capsule

  • Experimental
    Rifampicin DDI

    Rifampicin capsule, 0.6g once daily from Day 3 to Day 11. TQB3909 tablets, single oral dose on Day 1 and Day 10.

    Drug: TQB3909 tablets · Drug: Rifampicin capsule

Interventions

  • TQB3909 100mg/tablet.

  • DrugItraconazole capsule

    Itraconazole capsule is a strong inhibitor of CYP3A4.

  • DrugRifampicin capsule

    Rifampicin capsule is a strong inducer of CYP3A4.

06

What researchers measure

Primary outcomes

  1. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time to reach maximum (peak) plasma concentration following drug administration.

    Time frame: Inhibitor group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48, 72 hours (only on Day 8) after dose on Day 1 and Day 8. Inducer group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48 hours after dose on Day 1 and Day 10.

  2. Maximum Plasma Concentration (Cmax)

    The maximum observed plasma concentration of TQB3909

    Time frame: Inhibitor group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48, 72 hours (only on Day 8) after dose on Day 1 and Day 8. Inducer group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48 hours after dose on Day 1 and Day 10.

  3. Elimination half-life (t1/2)

    The time required for half of the drug to be eliminated from the plasma.

    Time frame: Inhibitor group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48, 72 hours (only on Day 8) after dose on Day 1 and Day 8. Inducer group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48 hours after dose on Day 1 and Day 10.

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Incidence of adverse events (AEs) based on the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0

    Time frame: Up to 12 days.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2023; primary completion for Jan 2024, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2023
First posted
Dec 12, 2023
StartEst.
Dec 2023
Primary completionEst.
Jan 2024
CompletionEst.
Mar 2024
Last update
Dec 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06165822
Responsible party
Sponsor
First posted
Dec 12, 2023
Start date
Dec 2023 (estimated)
Primary completion
Jan 2024 (estimated)
Completion
Mar 2024 (estimated)
Last update
Dec 12, 2023

Study contacts

Fei Hua, MD, PhD
Contact
czyyphase1@163.com
0519-68870002
Weiying Gu, MD, PhD
Contact
guweiying2001@163.com
0519-68871092

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bcl-2 Inhibitor TQB3909

Start the discussion